SUVEN PHARMACEUTICALS
|
SUVEN PHARMACEUTICALS Last 5 Year Balance Sheet History
[Consolidated]
Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
---|---|---|---|---|---|
EQUITY AND LIABILITIES | |||||
Share Capital | ₹25 Cr | ₹25 Cr | ₹25 Cr | ₹25 Cr | ₹13 Cr |
Equity - Authorised | ₹40 Cr | ₹40 Cr | ₹40 Cr | ₹40 Cr | ₹20 Cr |
Equity - Issued | ₹25 Cr | ₹25 Cr | ₹25 Cr | ₹25 Cr | ₹13 Cr |
Equity Paid Up | ₹25 Cr | ₹25 Cr | ₹25 Cr | ₹25 Cr | ₹13 Cr |
Equity Shares Forfeited | - | - | - | - | - |
Adjustments to Equity | - | - | - | - | - |
Preference Capital Paid Up | - | - | - | - | - |
Face Value | ₹1.00 | ₹1.00 | ₹1.00 | ₹1.00 | ₹1.00 |
Share Warrants & Outstandings | ₹2.00 Cr | - | - | - | - |
Total Reserves | ₹2,023 Cr | ₹1,710 Cr | ₹1,502 Cr | ₹1,155 Cr | ₹832 Cr |
Securities Premium | ₹110 Cr | ₹110 Cr | ₹110 Cr | ₹110 Cr | ₹122 Cr |
Capital Reserves | - | - | - | - | - |
Profit & Loss Account Balance | ₹1,765 Cr | ₹1,465 Cr | ₹1,273 Cr | ₹936 Cr | ₹615 Cr |
General Reserves | ₹124 Cr | ₹124 Cr | ₹109 Cr | ₹94 Cr | ₹79 Cr |
Other Reserves | ₹24 Cr | ₹11 Cr | ₹10 Cr | ₹15 Cr | ₹15 Cr |
Reserve excluding Revaluation Reserve | ₹2,023 Cr | ₹1,710 Cr | ₹1,502 Cr | ₹1,155 Cr | ₹832 Cr |
Revaluation reserve | - | - | - | - | - |
Shareholder's Funds | ₹2,051 Cr | ₹1,735 Cr | ₹1,527 Cr | ₹1,181 Cr | ₹845 Cr |
Minority Interest | - | - | - | - | - |
Long-Term Borrowings | - | - | - | - | - |
Secured Loans | - | ₹4.56 Cr | ₹28 Cr | ₹36 Cr | - |
Non Convertible Debentures | - | - | - | - | - |
Converible Debentures & Bonds | - | - | - | - | - |
Packing Credit - Bank | - | - | - | - | - |
Inter Corporate & Security Deposit | - | - | - | - | - |
Term Loans - Banks | - | ₹4.56 Cr | ₹28 Cr | ₹36 Cr | - |
Term Loans - Institutions | - | - | - | - | - |
Other Secured | - | - | - | - | - |
Unsecured Loans | - | - | - | - | ₹91 Cr |
Fixed Deposits - Public | - | - | - | - | - |
Loans and advances from subsidiaries | - | - | - | - | - |
Inter Corporate Deposits (Unsecured) | - | - | - | - | - |
Foreign Currency Convertible Notes | - | - | - | - | - |
Long Term Loan in Foreign Currency | - | - | - | - | - |
Loans - Banks | - | - | - | - | - |
Loans - Govt. | - | - | - | - | - |
Loans - Others | - | - | - | - | ₹91 Cr |
Other Unsecured Loan | - | - | - | - | - |
Deferred Tax Assets / Liabilities | ₹65 Cr | ₹58 Cr | ₹54 Cr | ₹31 Cr | ₹28 Cr |
Deferred Tax Assets | ₹4.48 Cr | ₹2.21 Cr | ₹1.48 Cr | ₹2.47 Cr | ₹1.94 Cr |
Deferred Tax Liability | ₹69 Cr | ₹60 Cr | ₹56 Cr | ₹33 Cr | ₹30 Cr |
Other Long Term Liabilities | ₹21 Cr | ₹0.70 Cr | ₹0.46 Cr | ₹0.74 Cr | ₹0.51 Cr |
Long Term Trade Payables | - | - | - | - | - |
Long Term Provisions | ₹11 Cr | ₹8.30 Cr | ₹8.90 Cr | ₹6.65 Cr | ₹8.32 Cr |
Total Non-Current Liabilities | ₹97 Cr | ₹72 Cr | ₹92 Cr | ₹74 Cr | ₹128 Cr |
Current Liabilities | - | - | - | - | - |
Trade Payables | ₹42 Cr | ₹70 Cr | ₹106 Cr | ₹83 Cr | ₹71 Cr |
Sundry Creditors | ₹42 Cr | ₹70 Cr | ₹106 Cr | ₹83 Cr | ₹71 Cr |
Acceptances | - | - | - | - | - |
Due to Subsidiaries- Trade Payables | - | - | - | - | - |
Other Current Liabilities | ₹21 Cr | ₹20 Cr | ₹30 Cr | ₹29 Cr | ₹28 Cr |
Bank Overdraft / Short term credit | - | - | - | - | - |
Advances received from customers | ₹0.69 Cr | ₹0.81 Cr | ₹3.80 Cr | ₹0.01 Cr | ₹1.20 Cr |
Interest Accrued But Not Due | - | - | - | - | - |
Share Application Money | - | - | - | - | - |
Current maturity of Debentures & Bonds | - | - | - | - | - |
Current maturity - Others | - | - | - | - | - |
Other Liabilities | ₹21 Cr | ₹19 Cr | ₹26 Cr | ₹29 Cr | ₹26 Cr |
Short Term Borrowings | ₹39 Cr | ₹65 Cr | ₹67 Cr | ₹106 Cr | ₹94 Cr |
Secured ST Loans repayable on Demands | ₹39 Cr | ₹65 Cr | ₹67 Cr | ₹64 Cr | ₹26 Cr |
Working Capital Loans- Sec | ₹39 Cr | ₹45 Cr | ₹47 Cr | ₹44 Cr | ₹26 Cr |
Buyers Credits - Unsec | - | - | - | - | - |
Commercial Borrowings- Unsec | - | - | - | - | - |
Other Unsecured Loans | ₹-39 Cr | ₹-45 Cr | ₹-47 Cr | ₹-2.74 Cr | ₹42 Cr |
Short Term Provisions | ₹104 Cr | ₹149 Cr | ₹145 Cr | ₹104 Cr | ₹127 Cr |
Proposed Equity Dividend | - | - | - | - | - |
Provision for Corporate Dividend Tax | - | - | - | - | - |
Provision for Tax | ₹99 Cr | ₹145 Cr | ₹141 Cr | ₹102 Cr | ₹125 Cr |
Provision for post retirement benefits | - | - | - | - | - |
Preference Dividend | - | - | - | - | - |
Other Provisions | ₹4.74 Cr | ₹3.95 Cr | ₹4.08 Cr | ₹2.61 Cr | ₹2.52 Cr |
Total Current Liabilities | ₹206 Cr | ₹303 Cr | ₹348 Cr | ₹322 Cr | ₹320 Cr |
Total Liabilities | ₹2,353 Cr | ₹2,110 Cr | ₹1,967 Cr | ₹1,576 Cr | ₹1,292 Cr |
ASSETS | |||||
Gross Block | ₹927 Cr | ₹876 Cr | ₹694 Cr | ₹570 Cr | ₹457 Cr |
Less: Accumulated Depreciation | ₹258 Cr | ₹212 Cr | ₹160 Cr | ₹128 Cr | ₹100 Cr |
Less: Impairment of Assets | - | - | - | - | - |
Net Block | ₹670 Cr | ₹663 Cr | ₹534 Cr | ₹441 Cr | ₹357 Cr |
Lease Adjustment A/c | - | - | - | - | - |
Capital Work in Progress | ₹179 Cr | ₹165 Cr | ₹30 Cr | ₹96 Cr | ₹102 Cr |
Non Current Investments | ₹131 Cr | ₹117 Cr | ₹117 Cr | ₹361 Cr | ₹307 Cr |
Long Term Investment | ₹131 Cr | ₹117 Cr | ₹117 Cr | ₹361 Cr | ₹307 Cr |
Quoted | - | - | - | - | - |
Unquoted | ₹131 Cr | ₹117 Cr | ₹117 Cr | ₹361 Cr | ₹307 Cr |
Long Term Loans & Advances | ₹11 Cr | ₹9.19 Cr | ₹13 Cr | ₹11 Cr | ₹15 Cr |
Other Non Current Assets | ₹0.21 Cr | - | ₹7.30 Cr | ₹0.16 Cr | ₹0.20 Cr |
Total Non-Current Assets | ₹991 Cr | ₹955 Cr | ₹702 Cr | ₹910 Cr | ₹781 Cr |
Current Assets Loans & Advances | - | - | - | - | - |
Currents Investments | ₹774 Cr | ₹419 Cr | ₹481 Cr | ₹181 Cr | ₹31 Cr |
Quoted | ₹774 Cr | ₹378 Cr | ₹451 Cr | - | - |
Unquoted | - | ₹41 Cr | ₹30 Cr | ₹181 Cr | ₹31 Cr |
Inventories | ₹231 Cr | ₹313 Cr | ₹283 Cr | ₹201 Cr | ₹175 Cr |
Raw Materials | ₹46 Cr | ₹77 Cr | ₹72 Cr | ₹51 Cr | ₹35 Cr |
Work-in Progress | ₹101 Cr | ₹113 Cr | ₹132 Cr | ₹98 Cr | ₹77 Cr |
Finished Goods | ₹63 Cr | ₹99 Cr | ₹60 Cr | ₹33 Cr | ₹46 Cr |
Packing Materials | ₹4.43 Cr | ₹4.04 Cr | ₹2.55 Cr | ₹3.00 Cr | ₹1.86 Cr |
Stores  and Spare | ₹17 Cr | ₹19 Cr | ₹17 Cr | ₹15 Cr | ₹16 Cr |
Other Inventory | - | - | - | - | - |
Sundry Debtors | ₹134 Cr | ₹111 Cr | ₹236 Cr | ₹102 Cr | ₹117 Cr |
Debtors more than Six months | - | - | - | - | - |
Debtors Others | ₹134 Cr | ₹111 Cr | ₹236 Cr | ₹102 Cr | ₹117 Cr |
Cash and Bank | ₹50 Cr | ₹68 Cr | ₹47 Cr | ₹9.65 Cr | ₹14 Cr |
Cash in hand | ₹0.06 Cr | ₹0.05 Cr | ₹0.09 Cr | ₹0.09 Cr | ₹0.12 Cr |
Balances at Bank | ₹50 Cr | ₹68 Cr | ₹47 Cr | ₹9.56 Cr | ₹14 Cr |
Other cash and bank balances | - | - | - | - | - |
Other Current Assets | ₹12 Cr | ₹11 Cr | ₹11 Cr | ₹12 Cr | ₹9.13 Cr |
Interest accrued on Investments | ₹0.43 Cr | ₹0.28 Cr | - | - | - |
Interest accrued on Debentures | - | - | - | - | - |
Deposits with Government | - | - | - | - | - |
Interest accrued and or due on loans | - | - | - | - | - |
Prepaid Expenses | ₹4.92 Cr | ₹8.63 Cr | ₹6.40 Cr | ₹4.40 Cr | ₹3.86 Cr |
Other current_assets | ₹6.55 Cr | ₹2.55 Cr | ₹4.47 Cr | ₹7.44 Cr | ₹5.27 Cr |
Short Term Loans and Advances | ₹161 Cr | ₹233 Cr | ₹206 Cr | ₹161 Cr | ₹165 Cr |
Advances recoverable in cash or in kind | ₹1.97 Cr | ₹25 Cr | ₹24 Cr | ₹13 Cr | ₹15 Cr |
Advance income tax and TDS | ₹109 Cr | ₹144 Cr | ₹137 Cr | ₹104 Cr | ₹119 Cr |
Amounts due from directors | - | - | - | - | - |
Due From Subsidiaries | - | - | - | - | - |
Inter corporate deposits | - | - | - | - | - |
Corporate Deposits | - | - | - | - | - |
Other Loans & Advances | ₹50 Cr | ₹64 Cr | ₹45 Cr | ₹44 Cr | ₹31 Cr |
Total Current Assets | ₹1,362 Cr | ₹1,155 Cr | ₹1,265 Cr | ₹667 Cr | ₹511 Cr |
Net Current Assets (Including Current Investments) | ₹1,156 Cr | ₹852 Cr | ₹918 Cr | ₹345 Cr | ₹191 Cr |
Miscellaneous Expenses not written off | - | - | - | - | - |
Total Assets | ₹2,353 Cr | ₹2,110 Cr | ₹1,967 Cr | ₹1,576 Cr | ₹1,292 Cr |
Contingent Liabilities | ₹16 Cr | ₹6.07 Cr | ₹6.07 Cr | ₹6.07 Cr | ₹9.51 Cr |
Total Debt | ₹39 Cr | ₹69 Cr | ₹96 Cr | ₹141 Cr | ₹185 Cr |
Book Value | - | 68.16 | 59.99 | 46.39 | 66.37 |
Adjusted Book Value | 80.48 | 68.16 | 59.99 | 46.39 | 33.18 |
Compare Balance Sheet of peers of SUVEN PHARMACEUTICALS
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
SUVEN PHARMACEUTICALS | ₹30,065.7 Cr | -6.9% | -7.5% | 75.9% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹433,920.0 Cr | -0.1% | 1.7% | 45.7% | Stock Analytics | |
DIVIS LABORATORIES | ₹155,160.0 Cr | -0.1% | -2.2% | 56.9% | Stock Analytics | |
CIPLA | ₹118,917.0 Cr | 1.7% | 0.5% | 23.7% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹112,017.0 Cr | 5.7% | 12.4% | 18.5% | Stock Analytics | |
ZYDUS LIFESCIENCES | ₹97,997.1 Cr | -1.4% | 3.1% | 44.8% | Stock Analytics |
SUVEN PHARMACEUTICALS Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
SUVEN PHARMACEUTICALS | -6.9% |
-7.5% |
75.9% |
SENSEX | -5% |
0.6% |
9.2% |
You may also like the below Video Courses